Delirium and Heart Failure

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age60+
SponsorAin Shams University

About this trial

Biomarkers such as Systemic Immune-Inflammation Index (SII) and TG/Glucose Ratio (TyG) have shown promise in predicting delirium, reflecting the roles of inflammation and metabolic disturbances in its pathophysiology. This study aims to compare the predictive value of SII and the TyG ratio among other chemical and physiological biomarkers for diagnosing delirium and detecting its severity in older adults with heart failure. These biomarkers reflect different pathophysiological pathways implicated in delirium, including inflammation, cardiovascular stress, and metabolic dysfunction. By evaluating their individual and combined predictive abilities, this research seeks to identify potential tools for early identification of patients at high risk for delirium

Eligibility criteria

Qualifiers

None

Disqualifiers

cognitive impairment

Major Neurological Conditions: (e.g., stroke, traumatic brain injury).

Hematological diseases that affect platelet, neutrophil, and lymphocyte counts.

Cardiogenic Shock

Trial design

Treatments tested in this trial

  • Comprehensive Geriatric Assessment
  • the Confusion Assessment Method (CAM test) or CAM-ICU
  • Delirium Rating Scale - Revised-98
  • blood biomarkers

Treatment groups

100 Participants
are divided into 2 treatment groups

Sponsors and collaborators